A New Approach to Alzheimer's
Alzheimer's disease has long been treated with a single-minded focus: remove amyloid plaques from the brain. But a groundbreaking Phase 1b clinical trial published in Nature Medicine suggests that approach may be missing the bigger picture. Instead of targeting amyloid directly, researchers have found that rejuvenating the body's immune system can reduce neurodegenerative biomarkers and slow disease progression.
The trial evaluated IBC-Ab002, a novel humanized anti-PD-L1 monoclonal antibody developed by ImmunoBrain, a company co-founded by Prof. Michal Schwartz of the Weizmann Institute of Science. The results, published August 4, 2026, show the treatment was safe and well-tolerated across all tested doses, while also demonstrating biological activity that reduced markers of neuronal damage and synaptic loss in early-stage Alzheimer's patients.
How IBC-Ab002 Works: Targeting the Immune System, Not Amyloid
Traditional Alzheimer's therapies work by binding directly to amyloid beta plaques inside the brain, attempting to physically clear them away. IBC-Ab002 takes a completely different approach. Instead of targeting plaques, it acts on the peripheral immune system outside the brain by blocking the PD-L1 checkpoint.
This brief blockade lifts the "brakes" on the immune system, allowing systemic immune signaling to enter the central nervous system environment. The result is reduced chronic inflammation and support for tissue maintenance.
"The goal of our biological therapy is to restore the immune system's youthful capacity to protect the brain, thereby helping to arrest the disease or even reverse its course," says Prof. Schwartz. "We believe this approach could usher in a new era in the treatment of dementia and other neurodegenerative diseases, whose prevalence continues to rise as populations age and life expectancy increases."
The therapy was specifically engineered for Alzheimer's treatment with Fc-effector silencing and reduced FcRn binding, ensuring short-lived action tailored to the needs of neurodegenerative disease management. While IBC-Ab002 targets the same immune checkpoint molecule as anti-PD-L1 antibodies used in cancer immunotherapy, its distinctive properties make it uniquely suited for Alzheimer's.
Trial Results: Safety and Tolerability Confirmed
The multicenter, international Phase 1b trial enrolled 40 patients with early-stage Alzheimer's disease across 11 medical centers: five in the United Kingdom, five in Israel, and one in the Netherlands. The trial was led by Dr. Tommaso Croese, formerly a PhD student in Schwartz's lab and now vice president of clinical development at ImmunoBrain, together with Prof. Catherine J. Mummery of the Dementia Research Centre at University College London.
Key findings include:
- Safety confirmed: The treatment was safe and well-tolerated at all tested doses, ranging from 1 to 30 mg/kg.
- No serious adverse events: No treatment-related serious adverse events were observed during the trial.
- No amyloid-related imaging abnormalities: The trial showed no evidence of amyloid-related imaging abnormalities, a common concern with amyloid-targeting therapies.
- Clear target engagement: Biological evaluation confirmed that the treatment achieved its intended mechanism of action.
Dosing was administered four times at 3-month intervals across five ascending dose cohorts. The trial's primary objective, as is standard for Phase 1 trials, was to evaluate safety—a goal it achieved with flying colors.
Biomarker Reductions: Evidence of Neuroprotection
Beyond meeting all primary safety endpoints, the trial revealed encouraging biological outcomes. Exploratory analyses at week 48 showed directional changes in cerebrospinal fluid biomarkers of neuronal and synaptic damage, favoring the 30 mg/kg dose.
Specifically, the treatment reduced biomarkers of active neuronal injury and reversed markers associated with synaptic loss. While no doses reached statistical significance given the limited sample size, the directional changes support the therapy's potential for neuroprotection.
"These findings support further clinical development of this innovative therapeutic strategy," the researchers concluded. The trial's registration number on ClinicalTrials.gov is NCT05551741.
The Science Behind the Breakthrough: Prof. Schwartz's Pioneering Work
The foundation for IBC-Ab002 rests on decades of research by Prof. Michal Schwartz, a recipient of the Israel Prize in Life Sciences. Her work overturned the long-held dogma that the brain was entirely isolated from immune activity and that any immune activity within the brain was inherently detrimental.
Schwartz revealed the critical role of age-related immune dysfunction in driving the progression of brain aging. Her research showed that regardless of a neurodegenerative disease's primary cause, age-related decline of the immune system fuels brain inflammation—a major driver of disease progression. This finding suggested that removing amyloid plaques, long considered a hallmark of Alzheimer's, is not sufficient to halt the disease.
About a decade ago, using mouse models of Alzheimer's disease and other forms of dementia, Schwartz's team demonstrated that transient, intermittent reduction of the suppression imposed on the immune system by inhibitory immune checkpoints promotes the clearance of aging cells from the diseased brain, reduces brain inflammation, and alleviates disease symptoms.
"Ageing is the greatest risk factor for Alzheimer's disease," Schwartz notes. "Our research over the years has shown that one of the key contributors to disease progression is the aging of the immune system. Age-related decline in immune function fuels chronic inflammation in the brain, a major driver of the progression of Alzheimer's disease and other neurodegenerative disorders."
What's Next for IBC-Ab002?
The Phase 1b trial's results—demonstrating both safety and biological activity—support further clinical development of systemic, intermittently administered IBC-Ab002 in early Alzheimer's disease. The therapy represents a paradigm shift in treating neurodegenerative diseases by addressing systemic immune aging rather than just brain pathology.
ImmunoBrain licensed the underlying technology and intellectual property from Yeda, the Weizmann Institute's tech transfer company, and developed IBC-Ab002 based on this newly discovered immune mechanism. The company's dedication to translating Schwartz's research into therapies for neurodegenerative diseases could soon yield tangible benefits for patients.
Other participants in the study included Dr. Noa Bregman of Tel Aviv Sourasky University Medical Center (Ichilov) and Tel Aviv University, along with Dalia Bracha, Dr. Kuti Baruch, Dr. Alexander Kertser, Dr. Sharona Raveh, and Dr. Eliezer Shochat of ImmunoBrain.
As populations age and life expectancy increases, the prevalence of Alzheimer's and other neurodegenerative diseases continues to rise. IBC-Ab002's novel approach to targeting the immune system rather than amyloid plaques offers hope for a new generation of treatments that address the root causes of neurodegeneration rather than just its symptoms.
Research Notes
Key angle: Novel non-amyloid approach to Alzheimer's treatment. Traditional therapies target amyloid plaques directly; IBC-Ab002 works by rejuvenating the immune system to clear senescent cells and reduce neuroinflammation. This represents a paradigm shift in treating neurodegenerative diseases by addressing systemic immune aging rather than just brain pathology.
Important context: Prof. Michal Schwartz (Weizmann Institute) pioneered this approach, overturning the long-held belief that brain immune activity is inherently detrimental. The therapy was engineered with Fc-effector silencing and reduced FcRn binding for short-lived action tailored to Alzheimer's treatment.
Source: https://neurosciencenews.com/antibody-alzheimers-immunotherapy-31179/
- Phase 1b clinical trial evaluated IBC-Ab002, a humanized anti-PD-L1 monoclonal antibody, in patients with early-stage Alzheimer's disease
- The treatment was safe and well-tolerated at all administered doses (ranging from 1 to 30 mg/kg)
- No treatment-related serious adverse events were observed
- No amyloid-related imaging abnormalities occurred
- Treatment reduced biomarkers of active neuronal injury and reversed markers associated with synaptic loss
- Exploratory analyses showed directional changes in cerebrospinal fluid biomarkers favoring the 30 mg/kg dose, though not statistically significant due to sample size
- The therapy targets the PD-1/PD-L1 inhibitory immune checkpoint to rejuvenate peripheral immune activity rather than directly removing amyloid plaques
- Mechanism involves clearing senescent cells and dampening brain inflammation
- Clinical trial spanned 11 sites across five in the UK, five in Israel, and one in the Netherlands
- 40 participants were enrolled in the multicenter, international Phase 1 trial
- Dosing was administered four times at 3-month intervals
- Published in Nature Medicine (DOI:10.1038/s43856-026-01767-4)
- ClinicalTrials.gov registration: NCT05551741
